PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases
NCT ID: NCT01125605
Last Updated: 2015-04-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
325 participants
OBSERVATIONAL
2010-05-31
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep
NCT00997256
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
NCT00209950
Usage of Baclofen for Sleep Improvement After Cardiac Surgery
NCT02529514
Neurexan - a Clinical Trial in Short-Term Insomnia Patients
NCT06278077
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance
NCT00991276
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management, dose regimen, and to the effectiveness and safety in special patient groups (children 1-12 years of age), in relation to treatment conformity to the Summary of Product Characteristics (SmPC).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults > 12 years
adult patients and patients older than 12 years
No interventions assigned to this group
Children 6-12 years
children between 6 and 12 years
No interventions assigned to this group
Children 1-6 years
children between 1 and 6 years
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children 1-12 years old
* Adults \>12 years old
* suffering from nervous diseases, e.g. sleep disorders due to nervousness.
Exclusion Criteria
* no nervous diseases, e.g. sleep disorders due to nervousness.
* no treatment with PASCONAL NERVENTROPFEN
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pascoe Pharmazeutische Praeparate GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bianka Krick
Role: STUDY_DIRECTOR
Pascoe Pharmazeutische Praeparate GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple German Practices
All Over Germany, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
174A10PNAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.